Treatment of Urinary Schistosomiasis in Ghanaians with TWSb (Astiban®)

Martin S. Wolfe Clinical Investigations Unit, National Institutes of Health (U.S.A.)-National Institutes of Health and Medical Research (Ghana)-Joint Research Program, U. S. Public Health Service, Accra, Ghana

Search for other papers by Martin S. Wolfe in
Current site
Google Scholar
Restricted access


Ambulatory treatment with TWSb gave a 93 percent presumptive cure rate in 28 patients with urinary schistosomiasis. All of the patients treated were improved symptomatically.

Side effects were considerable, but relatively few were severe. Only one patient refused further treatment because of side effects.

The high cure rate and short and convenient course of five injections may overweigh the disadvantages of frequent side effects and expense of the drug.

It is recommended that TWSb may be used advantageously in carefully selected and closely observed outpatients, but it is not suited for indiscriminate mass ambulatory treatment.

Author Notes

Present address: Second (Cornell) Medical Division, Bellevue Hospital, New York, N. Y.